Literature DB >> 17033583

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases.

Pär I Johansson1, Kirsten Eriksen, Bjarme Alsbjørn.   

Abstract

Major burn wound excision is associated with excessive perioperative blood loss. Treatment of massive microvascular bleeding represents a special problem in the burn setting, characterized by extensive damage at the capillary level, and resulting in a profound blood loss; which together with the consumptive states makes adequate replacement therapy with coagulation factors and platelets difficult. We described our experience with rescue treatment with rFVIIa in four patients undergoing major wound excision, developing life-threatening perioperative bleeding, and not responding to conventional therapy. Hemostasis was achieved within 15 minutes of intravenous rFVIIa administration, at a dose of 100 microg/kg, in all patients. No treatment-related adverse events, in particular, no thromboembolic events were observed. We conclude that rFVIIa may be an effective hemostatic treatment for patients undergoing major wound excision developing life-threatening bleedings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033583     DOI: 10.1097/01.ta.0000239261.48022.f1

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  3 in total

Review 1.  V.A.C. Therapy in the management of paediatric wounds: clinical review and experience.

Authors:  Mona Baharestani; Ibrahim Amjad; Kim Bookout; Tatjana Fleck; Allen Gabriel; David Kaufman; Shannon Stone McCord; Donald C Moores; Oluyinka O Olutoye; Jorge D Salazar; David H Song; Steven Teich; Subhas Gupta
Journal:  Int Wound J       Date:  2009-08       Impact factor: 3.315

2.  Utilization of recombinant activated factor VII for intracranial hematoma evacuation in coagulopathic nonhemophilic neurosurgical patients with normal international normalized ratios.

Authors:  Shearwood McClelland; Eun Kyung Won; Cornelius H Lam
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

3.  Recombinant factor VIIa: hemostatic adjunct in the coagulopathic burn patient.

Authors:  Jeremiah T Martin; Fuad Alkhoury; Bryan C McIntosh; Phillip Fidler; John Schulz
Journal:  Eplasty       Date:  2009-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.